Enanta Pharmaceuticals Inc ENTA.OQ ENTA.O is expected to show a fall in quarterly revenue when it reports results on November 25 for the period ending September 30 2024
The Watertown Massachusetts-based company is expected to report a 5.3% decrease in revenue to $17.932 million from $18.93 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Enanta Pharmaceuticals Inc is for a loss of $1.16 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $22.00, above its last closing price of $9.31.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.40 | -1.45 | -1.07 | Beat | 26.2 |
Mar. 31 2024 | -1.39 | -1.30 | -1.47 | Missed | -13.2 |
Dec. 31 2023 | -1.19 | -1.19 | -1.58 | Missed | -32.3 |
Sep. 30 2023 | -2.17 | -2.15 | -1.33 | Beat | 38 |
Jun. 30 2023 | -2.37 | -2.34 | -1.86 | Beat | 20.4 |
Mar. 31 2023 | -1.94 | -1.98 | -1.79 | Beat | 9.6 |
Dec. 31 2022 | -1.59 | -1.59 | -1.39 | Beat | 12.9 |
Sep. 30 2022 | -1.40 | -1.35 | -1.27 | Beat | 6.1 |
This summary was machine generated November 22 at 21:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。